Literature DB >> 32425472

Electroconvulsive Therapy for Geriatric Depression in the COVID-19 Era: Reflection on the Ethics.

Amer M Burhan1, Ajmal Safi2, Mervin Blair2, Richard O'Reilly3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32425472      PMCID: PMC7227591          DOI: 10.1016/j.jagp.2020.05.007

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


× No keyword cloud information.
Electroconvulsive therapy (ECT) is a highly effective treatment for severe, life-threatening and/or treatment resistant geriatric depression. , WHO declared COVID-19 as a pandemic in March 2020.3 This illness carries high risk of morbidity and mortality in geriatric patients. , ECT is a procedure that involves open airway management and has been considered an aerosol generating procedure. , Though risk of transmission from ECT is still unknown, psychiatric services are challenged in providing ECT as an essential service while reducing the risk of COVID-19 spread. Several hospitals immediately shut down their ECT service leaving seriously ill geriatric patients untreated. Mortality and morbidity rate from geriatric depression due to suicide and physical deterioration is relatively high. , Mortality and morbidity from COVID-19 is still unclear, though geriatric patients are likely at higher risk. This creates a serious ethical dilemma to balance between the risk from untreated depression versus the risk from COVID-19. To balance between the ethical principles of autonomy, beneficence, nonmaleficence and justice is a significant challenge in this context. Our approach at the at the Parkwood Institute-Mental Health Care Building, an academic site of Western University in London Ontario Canada, is to go through a rigorous patient prioritization process (see Fig. 1 ), which is largely modeled after the recently published International Society for ECT and Neurostimulation recommendations. We colour-code cases to red (emergent), orange (highly urgent), yellow (urgent but can wait for up to 4 weeks), green (can be clinically monitored without treatment but provide quick access if the acuity changes) and gray (stable long term, can be re-referred for new episode of illness). For those that we select for treatment, we go through a revision of the informed consent procedure to reflect the added risk of infection. We then conduct the ECT procedure in an ECT room that is modified to provide negative pressure and allow optimum air circulation between patients. All staff providing ECT are geared in full personal protective equipment, which is changed between patients while the room is being ventilated and sterilized. Prior to ECT, patients are screened clinically for COVID-19 status, and if screened positive, we would test for the virus using PCR. COVID-19 + status will require added precautions in consultation with the infection disease pandemic management team in the hospital. Out of the list of 45 patients, we triaged 2 to red zone, 6 to orange zone, 3 to yellow zone, 17 to green and 17 to gray zone. We were able to start or re-start ECT to all of those in the red and orange zone within a week of initiating this process.
FIGURE 1

Patient Prioritization for ECT Treatment in the COVID-19 era.

Patient Prioritization for ECT Treatment in the COVID-19 era. It is our contention that seniors with life-threatening and/or severely distressing depression need to be prioritized to receive ECT as long as we follow a thoughtful selection process and infection control practices as outlined above. We intend to reflect on our practice postpandemic to evaluate the outcome from this practice to inform the field regarding pandemic and crisis preparedness in relation to severe mental illness and the use of ECT.

AUTHORS CONTRIBUTION

Amer M. Burhan: Initiated and conceptualized the paper, assigned tasks to other authors, corresponded with the editor, responded to reviewer, and finalized the paper in its current form. Ajmal Safi: Searched, collected and summarized references used in this manuscript and worked with the third author on developing the first draft of the paper. Mervin Blair: Revised and finalized the first draft of the paper, contributed to the concept on ethical principles. Richard O'Reilly: Developed the triage system reported in the paper, reported results to the first author, reviewed the manuscript and suggested modifications.
  8 in total

Review 1.  Electroconvulsive Therapy in the Elderly: New Findings in Geriatric Depression.

Authors:  Emma T Geduldig; Charles H Kellner
Journal:  Curr Psychiatry Rep       Date:  2016-04       Impact factor: 5.285

Review 2.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

3.  Association between depression and mortality in older adults: the Cardiovascular Health Study.

Authors:  R Schulz; S R Beach; D G Ives; L M Martire; A A Ariyo; W J Kop
Journal:  Arch Intern Med       Date:  2000-06-26

Review 4.  Medical ethics: four principles plus attention to scope.

Authors:  R Gillon
Journal:  BMJ       Date:  1994-07-16

5.  Late-life depression and mortality: influence of gender and antidepressant use.

Authors:  Joanne Ryan; Isabelle Carriere; Karen Ritchie; Robert Stewart; Gwladys Toulemonde; Jean-François Dartigues; Christophe Tzourio; Marie-Laure Ancelin
Journal:  Br J Psychiatry       Date:  2008-01       Impact factor: 9.319

6.  Electroconvulsive Therapy in a Time of Coronavirus Disease.

Authors:  Phern Chern Tor; Adeline H H Phu; Doris S H Koh; Yee Ming Mok
Journal:  J ECT       Date:  2020-06       Impact factor: 3.692

Review 7.  Virology, Epidemiology, Pathogenesis, and Control of COVID-19.

Authors:  Yuefei Jin; Haiyan Yang; Wangquan Ji; Weidong Wu; Shuaiyin Chen; Weiguo Zhang; Guangcai Duan
Journal:  Viruses       Date:  2020-03-27       Impact factor: 5.048

Review 8.  COVID-19: what has been learned and to be learned about the novel coronavirus disease.

Authors:  Ye Yi; Philip N P Lagniton; Sen Ye; Enqin Li; Ren-He Xu
Journal:  Int J Biol Sci       Date:  2020-03-15       Impact factor: 6.580

  8 in total
  5 in total

Review 1.  The Use of ECT in the Elderly-Looking Beyond Depression.

Authors:  Anthony N Chatham; Hadia Shafi; Adriana P Hermida
Journal:  Curr Psychiatry Rep       Date:  2022-07-13       Impact factor: 8.081

2.  Electroconvulsive Therapy in Canada During the First Wave of COVID-19: Results of the "What Happened" National Survey.

Authors:  Ilya Demchenko; Daniel M Blumberger; Alastair J Flint; Melanie Anderson; Zafiris J Daskalakis; Karen Foley; Keyvan Karkouti; Sidney H Kennedy; Karim S Ladha; Jamie Robertson; Alon Vaisman; David Koczerginski; Sagar V Parikh; Venkat Bhat
Journal:  J ECT       Date:  2022-03-01       Impact factor: 3.692

Review 3.  One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach.

Authors:  Allen Y Chang; Kimberly N Babb
Journal:  Can Geriatr J       Date:  2022-06-01

4.  Psychotropics and COVID-19: An analysis of safety and prophylaxis.

Authors:  H Javelot; C Straczek; G Meyer; C Gitahy Falcao Faria; L Weiner; D Drapier; E Fakra; P Fossati; S Weibel; S Dizet; B Langrée; M Masson; R Gaillard; M Leboyer; P M Llorca; C Hingray; E Haffen; A Yrondi
Journal:  Encephale       Date:  2021-09-02       Impact factor: 1.291

5.  Electroconvulsive Therapy Practice Changes in Older Individuals Due to COVID-19: Expert Consensus Statement.

Authors:  Maria I Lapid; Stephen Seiner; Hannah Heintz; Adriana P Hermida; Louis Nykamp; Sohag N Sanghani; Martina Mueller; Georgios Petrides; Brent P Forester
Journal:  Am J Geriatr Psychiatry       Date:  2020-08-07       Impact factor: 4.105

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.